<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501955</url>
  </required_header>
  <id_info>
    <org_study_id>BMETEU.CR.EU88 MHP</org_study_id>
    <nct_id>NCT01501955</nct_id>
  </id_info>
  <brief_title>The Metaphyseal Hip Prosthesis - Total Hip</brief_title>
  <official_title>Evaluation of the Safety and Efficiency of the Metaphyseal Hip Prosthesis - Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze stability, safety and efficacy of the Metaphyseal Hip
      Prosthesis (MHP) compared to the Stanmore hip replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to analyze stability, safety and efficacy of the Metaphyseal Hip
      Prosthesis (MHP) compared to the Stanmore hip replacement at short term (1 year) and long
      term (10 years).

      Bone remodeling will be analyzed at 10 years using DEXA measurements. This is a single-center
      prospective study with 25 patients in the study and 25 in the control group in open
      Randomized Clinical Trial.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    First safety criterium not met.
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiostereometric Analysis (RSA)</measure>
    <time_frame>24 months postoperative</time_frame>
    <description>The short term stability (stem position) of the Metaphyseal Hip Prosthesis (MHP) will be analysed using Radiostereometric Analysis (RSA) to predict the long term survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device related complications</measure>
    <time_frame>10 years postoperative</time_frame>
    <description>Safety:
- Frequency of serious device related complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Harris Hip Score &amp; Hip Osteoarthritis Outcome Score</measure>
    <time_frame>10 years postoperative</time_frame>
    <description>Efficacy:
Functional outcome measured with HHS and HOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DEXA</measure>
    <time_frame>10 years postoperative</time_frame>
    <description>Efficacy:
Bone density measured using DEXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12</measure>
    <time_frame>10 years postoperative</time_frame>
    <description>Efficacy:
Quality of life measured with SF-12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Osteoarthritis of the Hip</condition>
  <arm_group>
    <arm_group_label>Stanmore</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 patients will have the Stanmore prosthesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metaphyseal Hip Prosthesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 patients will have the Metaphyseal Hip Prosthesis (MHP) prosthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Metaphyseal Hip Prosthesis</intervention_name>
    <description>Metaphyseal Hip Prosthesis (MHP) hip replacement</description>
    <arm_group_label>Metaphyseal Hip Prosthesis</arm_group_label>
    <other_name>The Metaphyseal Hip Prosthesis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stanmore</intervention_name>
    <description>Stanmore hip prosthesis</description>
    <arm_group_label>Stanmore</arm_group_label>
    <other_name>Stanmore hip prosthesis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Candidates for a total hip replacement because of arthritis of the hip

          -  Patients with a good general condition

          -  Patients willing and able to participate in the clinical trial with a 10 years follow
             up and who have signed an inform consent

          -  Males and females

          -  Age between 55 and 75

          -  Absence or little presence of osteoporotic bone (t&gt;-2)

          -  ASA score 1 and 2

        Exclusion Criteria:

          -  Patient with co morbidities that limit the physical abilities which may negatively
             influence the scores. Such co morbidities can for example be cardiac insufficiency or
             chronic respiratory diseases.

          -  Severe systematic diseases such as rheumatic arthritis and SLE.

          -  General osteoporosis (t&lt;-2).

          -  Hormonal conditions such as Paget disease, which reduces the bone density.

          -  Diseases that can negatively influence the 10 years life expectancy.

          -  Chronic use of corticosteroids.

          -  Extreme overweight defined as BMI above 35.

          -  Active bacterial infection.

          -  Mental weakness which could negatively influence the postoperative recovery and
             influence the ability to complete pain scores and other questionnaires.

          -  ASA score &gt;2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C.A.M.P. Bell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Franciscus Ziekenhuis Roosendaal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Franciscus Ziekenhuis Roosendaal</name>
      <address>
        <city>Roosendaal</city>
        <zip>4708</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2011</study_first_submitted>
  <study_first_submitted_qc>December 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2011</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 28, 2017</submitted>
    <returned>June 14, 2017</returned>
    <submitted>September 12, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>November 15, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

